Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02270892 · ClinicalTrials.gov registry record · NA
Ultherapy for Buttock Lift
A NA study, sponsored by Ulthera.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT02270892: Completed NA study, sponsored by Ulthera.
NCT02270892 is a NA study that has completed, run by Ulthera. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02270892, a NA study, has completed, sponsored by Ulthera.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
Up to 24 subjects will be enrolled and treated. Enrolled subjects will receive two Ulthera® treatments, 90 days apart. Follow-up visits will occur at 90, 180, and 270 days following the last treatment. Study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up visit.
Primary Outcome
Post-treatment change from baseline in protocol-defined buttock measurements: * ϒ (gamma) angle: The angle between the turning point between the gluteal sulcus line and the thigh; * β (beta) angle: The angle from the midpoint of the lateral thigh along the gluteal-sulcus line and the most posterior point of the buttock.
Interventions
- DEVICE Ulthera treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-08-28 |
| Est. Completion | 2017-04-03 |
| Phase | NA |
What the finished NCT02270892 record still lists
NCT02270892 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Ulthera treatment is the first listed.
NCT02270892 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02270892 about?
NCT02270892 is a clinical study titled "Ultherapy for Buttock Lift". Up to 24 subjects will be enrolled and treated. Enrolled subjects will receive two Ulthera® treatments, 90 days apart. Follow-up visits will occur at 90, 180, and 270 days following the last treatment. Study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up vis...
What is the current status of trial NCT02270892?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2014-08-28. Estimated completion is 2017-04-03.
What interventions are being tested in trial NCT02270892?
The interventions under investigation include: Ulthera treatment (DEVICE).
Who is sponsoring clinical trial NCT02270892?
This trial is sponsored by Ulthera, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02270892's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI